271 related articles for article (PubMed ID: 37467684)
21. Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?
Haddad RI; Harrington K; Tahara M; Szturz P; Le Tourneau C; Salmio S; Bajars M; Lee NY
Cancer Treat Rev; 2023 Sep; 119():102585. PubMed ID: 37392723
[TBL] [Abstract][Full Text] [Related]
22. De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control "always" matter?
Lorini L; Gili R; Salvestrini V; Morelli I; Smussi D; Petrelli F; Bonomo P; Bossi P
Oral Oncol; 2024 May; 152():106768. PubMed ID: 38552469
[TBL] [Abstract][Full Text] [Related]
23. Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial.
Tao Y; Auperin A; Blanchard P; Alfonsi M; Sun XS; Rives M; Pointreau Y; Castelli J; Graff P; Wong Hee Kam S; Thariat J; Veresezan O; Heymann S; Renard-Oldrini S; Lafond C; Cornely A; Casiraghi O; Boisselier P; Lapeyre M; Biau J; Bourhis J
Radiother Oncol; 2020 Sep; 150():18-25. PubMed ID: 32417348
[TBL] [Abstract][Full Text] [Related]
24. Concurrent cisplatin or cetuximab with radiotherapy in patients with locally advanced head and neck squamous cell carcinoma: A meta-analysis.
Tang WH; Sun W; Long GX
Medicine (Baltimore); 2020 Sep; 99(36):e21785. PubMed ID: 32899005
[TBL] [Abstract][Full Text] [Related]
25. Risk and impact of delayed renal impairment in patients with locally advanced head and neck squamous cell carcinoma receiving chemoradiotherapy with cisplatin.
Patimarattananan T; Nongnuch A; Pattaranutaporn P; Unwanatham N; Jiarpinitnun C; Ngamphaiboon N
Support Care Cancer; 2021 Feb; 29(2):877-887. PubMed ID: 32524284
[TBL] [Abstract][Full Text] [Related]
26. Novel approach of prophylactic radiation to reduce toxicities comparing 2-step40 with 56-Gy simultaneous integrated boost intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the head and neck, an intergroup phase III trial (JCOG1912, NEW BRIDGE).
Yokota T; Zenda S; Kodaira T; Kiyota N; Fujimoto Y; Wasano K; Takahashi R; Mizowaki T; Homma A; Sasaki K; Machida R; Sekino Y; Fukuda H; ;
BMC Cancer; 2023 Nov; 23(1):1068. PubMed ID: 37932681
[TBL] [Abstract][Full Text] [Related]
27. HIV Protease Inhibitors Sensitize Human Head and Neck Squamous Carcinoma Cells to Radiation by Activating Endoplasmic Reticulum Stress.
Liu R; Zhang L; Yang J; Zhang X; Mikkelsen R; Song S; Zhou H
PLoS One; 2015; 10(5):e0125928. PubMed ID: 25933118
[TBL] [Abstract][Full Text] [Related]
28. How Should We Approach Locally Advanced Squamous Cell Carcinoma of Head and Neck Cancer Patients Ineligible for Standard Non-surgical Treatment?
Yokota T; Hamauchi S; Shirasu H; Onozawa Y; Ogawa H; Onoe T; Onitsuka T
Curr Oncol Rep; 2020 Sep; 22(12):118. PubMed ID: 32945988
[TBL] [Abstract][Full Text] [Related]
29. Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma.
Schnoell J; Stanisz I; Jank BJ; Stanek V; Schmid R; Brunner M; Heiduschka G; Kotowski U
Invest New Drugs; 2022 Apr; 40(2):224-231. PubMed ID: 34613571
[TBL] [Abstract][Full Text] [Related]
30. Cisplatin overcomes radiotherapy resistance in OCT4-expressing head and neck squamous cell carcinoma.
Routila J; Qiao X; Weltner J; Rantala JK; Carpén T; Hagström J; Mäkitie A; Leivo I; Ruuskanen M; Söderlund J; Rintala M; Hietanen S; Irjala H; Minn H; Westermarck J; Ventelä S
Oral Oncol; 2022 Apr; 127():105772. PubMed ID: 35245886
[TBL] [Abstract][Full Text] [Related]
31. Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study.
Powell SF; Gold KA; Gitau MM; Sumey CJ; Lohr MM; McGraw SC; Nowak RK; Jensen AW; Blanchard MJ; Fischer CD; Bykowski J; Ellison CA; Black LJ; Thompson PA; Callejas-Valera JL; Lee JH; Cohen EEW; Spanos WC
J Clin Oncol; 2020 Jul; 38(21):2427-2437. PubMed ID: 32479189
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
33. Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer.
Zerp SF; Stoter TR; Hoebers FJ; van den Brekel MW; Dubbelman R; Kuipers GK; Lafleur MV; Slotman BJ; Verheij M
Radiat Oncol; 2015 Jul; 10():158. PubMed ID: 26223311
[TBL] [Abstract][Full Text] [Related]
34. Radiotherapy and chemotherapy in locally advanced head and neck squamous cell carcinoma.
Krstevska V
J BUON; 2009; 14(3):361-73. PubMed ID: 19810125
[TBL] [Abstract][Full Text] [Related]
35. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.
Yang L; Kumar B; Shen C; Zhao S; Blakaj D; Li T; Romito M; Teknos TN; Williams TM
Mol Cancer Ther; 2019 Jun; 18(6):1025-1035. PubMed ID: 31015310
[TBL] [Abstract][Full Text] [Related]
36. Loco-regional radiosensitizing nanoparticles-in-gel augments head and neck cancer chemoradiotherapy.
Bhardwaj P; Gota V; Vishwakarma K; Pai V; Chaudhari P; Mohanty B; Thorat R; Yadav S; Gurjar M; Goda JS; Banerjee R
J Control Release; 2022 Mar; 343():288-302. PubMed ID: 35101477
[TBL] [Abstract][Full Text] [Related]
37. Current landscape of immunotherapy trials in locally advanced and high-risk head and neck cancer.
Park R; Park JC
Immunotherapy; 2021 Aug; 13(11):931-940. PubMed ID: 34100301
[TBL] [Abstract][Full Text] [Related]
38. nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma.
Adkins D; Ley J; Michel L; Wildes TM; Thorstad W; Gay HA; Daly M; Rich J; Paniello R; Uppaluri R; Jackson R; Trinkaus K; Nussenbaum B
Oral Oncol; 2016 Oct; 61():1-7. PubMed ID: 27688097
[TBL] [Abstract][Full Text] [Related]
39. The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy.
Chen Y; Ding X; Bai X; Zhou Z; Liu Y; Zhang X; Yu J; Hu M
Int Immunopharmacol; 2023 Jul; 120():110329. PubMed ID: 37207445
[TBL] [Abstract][Full Text] [Related]
40. The comparison of acute toxicity in 2 treatment courses: Three-weekly and weekly cisplatin treatment administered with radiotherapy in patients with head and neck squamous cell carcinoma.
Mackiewicz J; Rybarczyk-Kasiuchnicz A; Łasińska I; Mazur-Roszak M; Świniuch D; Michalak M; Kaźmierska J; Studniarek A; Krokowicz Ł; Bajon T
Medicine (Baltimore); 2017 Dec; 96(51):e9151. PubMed ID: 29390445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
